Production (Stage)
Tango Therapeutics, Inc.
TNGX
$1.84
-$0.025-1.34%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.88M | -37.67M | -29.17M | -25.55M | -37.91M |
| Total Depreciation and Amortization | 622.00K | 620.00K | 622.00K | 632.00K | 625.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 7.57M | 7.55M | 6.93M | 7.30M | 6.26M |
| Change in Net Operating Assets | -10.02M | -7.15M | -11.78M | -5.99M | -6.83M |
| Cash from Operations | -41.70M | -36.65M | -33.39M | -23.61M | -37.86M |
| Capital Expenditure | -51.00K | -124.00K | -115.00K | -320.00K | -195.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.65M | 52.18M | 32.69M | 13.02M | -11.01M |
| Cash from Investing | 30.60M | 52.06M | 32.57M | 12.70M | -11.20M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 2.00K | 969.00K | 2.40M | 1.31M | 42.98M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 2.00K | 969.00K | 2.40M | 1.31M | 42.98M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -11.10M | 16.38M | 1.58M | -9.60M | -6.08M |